Ser838
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser838  -  CDH1 (human)

Site Information
LVFDYEGsGsEAAsL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 465565

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 2 ) , mutation of modification site ( 1 ) , phospho-antibody ( 2 ) , western blotting ( 2 )
Disease tissue studied:
prostate cancer ( 2 )
Relevant cell line - cell type - tissue:
HEK293T (epithelial) ( 1 ) , LNCaP (prostate cell) ( 2 )

Upstream Regulation
Treatments:
hydroxyflutamide ( 2 ) , testosterone ( 2 ) , wortmannin ( 2 )

Downstream Regulation
Effects of modification on CDH1:
molecular association, regulation ( 1 )
Induce interaction with:
CTNNB1 (human) ( 1 )

References 

1

Zhao Y, et al. (2018) Nuclear E-Cadherin Acetylation Promotes Colorectal Tumorigenesis via Enhancing ¿¿-Catenin Activity. Mol Cancer Res
30401720   Curated Info

2

Górowska-Wójtowicz E, et al. (2017) Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro 40, 324-335
28163245   Curated Info

3

Inuzuka H, et al. (2012) Acetylation-dependent regulation of skp2 function. Cell 150, 179-93
22770219   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.